NCT06674096View on ClinicalTrials.gov

RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

December 30, 2029

Study Completion Date

June 30, 2030

Conditions
Double-expressor Lymphoma
Interventions
DRUG

RLC-CRCHOP

"Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:~rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.~Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.~maintenance treatment period: chidamide d1,4,8,11"

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER